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Abstract
Saccular intracranial aneurysms (IAs) are balloon-like dilations of the intracranial arterial wall; 
their hemorrhage commonly results in severe neurologic impairment and death. We report a 
second genome-wide association study with discovery and replication cohorts from Europe and 
Japan comprising 5,891 cases and 14,181 controls with Ԉ832,000 genotyped and imputed SNPs 
across discovery cohorts. We identified three new loci showing strong evidence for association 
with IA in the combined data set, including intervals near RBBP8 on 18q11.2 (OR=1.22, 
P=1.1×10-12), STARD13/KL on 13q13.1 (OR=1.20, P=2.5×10-9) and a gene-rich region on 
10q24.32 (OR=1.29, P=1.2×10-9). We also confirmed prior associations near SOX17 (8q11.23-
q12.1; OR=1.28, P=1.3×10-12) and CDKN2A/B (9p21.3; OR=1.31, P=1.5×10-22). It is noteworthy 
that several putative risk genes play a role in cell-cycle progression, potentially affecting 
proliferation and senescence of progenitor cell populations that are responsible for vascular 
formation and repair.
IA affects approximately 2% of the general population and arises from the action of multiple 
genetic and environmental risk factors1. We previously reported the first genome-wide 
association study (GWAS) of IA2 that identified three IA risk loci on chromosomes 
8q11.23-q12.1, 9p21.3 and 2q33.1 with P < 5×10-8. This previous study had limited power 
to detect loci imparting genotypic relative risk (GRR) < 1.35 (Supplementary Table 1).
To increase the power to detect additional loci of similar or smaller effect, we ascertained 
and whole-genome genotyped 2 new European case cohorts (n = 1,616) and collected 
genotyping data from 5 additional European control cohorts (Supplementary Note, n = 
11,955). We also increased the size of the original Japanese replication cohort and added a 
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new Japanese replication cohort (2,282 cases and 905 controls) (Table 1). The new 
combined cohort has nearly 3-fold more cases than the original cohort and increased our 
power to detect variants with modest effect sizes. For example, this study had 89% and 64% 
average power to detect common variants (minor allele frequencies ≥ 10%) with GRR of 
1.25 and 1.20, respectively (Supplementary Table 1).
All subjects were genotyped using the Illumina platform. The new as well as the previously 
analyzed genotyping data were subjected to well-established quality control (QC) measures 
(Supplementary Table 2). We sought to eliminate potential confounding due to population 
stratification and gender1,3 by matching cases and controls of the same gender based on 
inferred genetic ancestry. As previous studies4,5 demonstrated that the Finnish population 
forms an ancestry cluster distinct from other European populations like those included in 
this study, we analyzed our Finnish cohort independently from others. To maximize 
opportunities for genetic matching and analytic power, we analyzed all subjects in the 
remaining European cohorts together. The resulting matched case-control data consisted of 
808 cases and 4,393 controls in the Finnish (FI) cohort and 1,972 cases and 8,122 controls in 
the rest of the combined European (CE) cohort (Supplementary Table 3). We used the QC-
passed genotype data and phased chromosomes from the HapMap CEU sample to impute 
missing genotypes6. We based our further analyses on 831,534 SNPs that passed the QC 
filters both in the FI and CE samples (Table 1 and Supplementary Table 2).
We tested for association of each QC-passed SNP with IA using conditional logistic 
regression, assuming a log-additive effect of allele dosage. We corrected each cohort for 
residual overdispersion (Table 1) using genomic control7, and combined the results from FI 
and CE to obtain P-values, odds ratios (ORs) and confidence intervals (CIs) for the 
discovery cohort of 2,780 cases and 12,515 controls using a fixed-effects model.
To evaluate the strength of association, in addition to using P-values, we employed a 
Bayesian approach8. We used the Bayes factor (BF) that represents the fold-change of the 
odds of association before and after observing the data9, and the posterior probability of 
association (PPA), calculated through the BF, that provides a simple probabilistic measure 
of the evidence of association8,10. For every SNP, we assumed a uniform prior probability 
of association of 1/10,000 and set the prior of the logarithm of per-allele OR as a normal 
distribution with a 95% probability of the OR to be between 0.67 and 1.5, with larger 
weights for smaller effect sizes9,11.
From the discovery results, we eliminated 2 imputed SNPs that showed PPAs of 0.97 and 
0.94 as their association signals were not supported by surrounding genotyped SNPs and 
their genotypes were not confirmed by direct genotyping results (data not shown). This 
resulted in 831,532 QC-passed SNPs (Supplementary Table 2).
We observed 3 regions that showed very high PPA (> 0.995; Fig. 1a) and also a substantial 
excess of SNPs with P < 1×10-3 (1,295 SNPs versus 831 SNPs expected by chance) even 
after excluding those within previously identified associated regions2 (Fig. 1b). Moreover, 
we observed a strong correlation between the P-values and BFs for the upper tail of the 
distribution (Fig. 1c).
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We focused on 5 genomic regions (Fig. 1a) that contained at least one SNP with PPA > 0.5, 
for which the hypothesis of association with IA is more likely than the null hypothesis of no 
association. The PPAs and P-values of the most highly associated SNPs in these intervals 
ranged from 0.6621 to > 0.9999 and 7.9×10-7 to 2.2×10-16, respectively (Supplementary 
Table 4). The 5 chromosomal segments included 3 newly identified SNP clusters at 
10q24.32, 13q13.1 and 18q11.2. The remaining 2 regions were previously identified loci at 
8q11.23-q12.1 and 9p21.32 (Fig. 2). The third locus identified in our previous study at 2q33 
did not contain any SNPs with PPA > 0.5. Furthermore, consistent with our previous 
results2, detailed analysis of the 8q11.23-q12.1 region detected two independent association 
signals within < 100 kb interval that spans the SOX17 locus (Fig. 2 and Supplementary Fig. 
1); hereafter these two signals are referred to as 5 ?-SOX17 and 3 ?-SOX17. Thus the 5 
chromosomal segments comprised 6 independent association signals for follow-up.
We performed replication genotyping in 2 Japanese cohorts including 3,111 cases and 1,666 
controls (JP1 and JP2, see Table 1). For each independent signal, we selected for replication 
the genotyped SNP with the highest PPA, and added up to 2 additional SNPs per locus. For 
the 5 ?-SOX17 region, we selected 2 SNPs analyzed previously, as they tag the best SNP in 
the current study (Supplementary Fig. 1).
All but one of the SNPs (rs12411886 on 10q24.32 in JP1) were successfully genotyped and 
passed QC filters. We tested for association of each SNP with IA using logistic regression 
stratified by gender, specifying the same model as for the discovery cohort (Supplementary 
Table 5). We combined results from JP1 and JP2 using a fixed-effects model (Table 2 and 
Supplementary Table 4). We considered an association to be replicated if the BF increased 
the odds of association > 10-fold after observing the replication data.
Of the 6 candidate loci, all but the 5 ?-SOX17 interval were replicated, with replication P-
values ranging from 0.0019 to 1.0×10-7 and the odds of association with IA increasing by 
22.9 to 1.5×105-fold, yielding robust evidence for replication for each interval (Table 2).
We combined the discovery and replication results using a fixed-effects model. All of the 5 
loci that replicated in the Japanese cohort surpassed the conventional threshold for genome-
wide significance (P < 5×10-8), with P-values ranging from 2.5×10-9 to 1.5×10-22, and all 
also had PPAs ≥ 0.998 (Table 2).
In order to determine each cohort' s contribution to the observed association and to assess the 
consistency of the effect size across cohorts, we analyzed each ascertained cohort separately 
(Table 1 and Supplementary Table 5) and then combined the results from the 6 cohorts using 
a random-effects model. The association results remained highly significant (Fig. 3). For the 
5 loci that were replicated in the Japanese cohorts, we found no evidence of significant 
heterogeneity across cohorts (P > 0.1). Every cohort had the same risk allele and provided 
support for association with the exception of JP1 cohort for the 3 ?-SOX17 locus, consistent 
with our previous study2 (Fig. 3).
The most significant association was detected in the previously reported2 9p21.3 region near 
CDKN2A and CDKN2B with P = 1.5×10-22 (OR = 1.32; PPA > 0.9999). All of the newly 
studied cohorts strongly supported this association with IA (Fig. 3). These same alleles are 
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also associated with coronary artery disease, but not with type 2 diabetes12. Similarly, the 
previously reported 8q11.23-q12.1 region showed significant association. The 3 ?-SOX17 
interval (rs92986506) showed robust association with P = 1.3×10-12 (OR = 1.28; PPA > 
0.9999) and all new cohorts supported association of this SNP with IA (Fig. 3). For the 5 ?-
SOX17 region (rs10958409), the new cohorts introduced a substantial heterogeneity across 
cohorts, lowering PPA to 0.016 (Fig. 3).
Among the newly identified loci, the strongest association was found at rs11661542 on 
18q11.2 (OR = 1.22; P = 1.1×10-12; PPA > 0.9999). A cluster of SNPs that are associated 
with IA spans the interval between 18.400Mb and 18.509Mb and are strongly correlated 
with rs11661542 (Fig. 2). A single gene, RBBP8 (retinoblastoma binding protein 8), is 
located within an extended linkage disequilibrium (LD) interval (Fig. 2).
The second strongest new association was at rs12413409 on 10q24.32 (OR = 1.29; P = 
1.2×10-9; PPA = 0.9990), which maps to intron 1 of CNNM2 (cyclin M2) (Fig. 2). A cluster 
of SNPs strongly correlated with rs12413409 and located within a Ԉ247kb interval in the 
same LD block supported the association (Fig. 2).
The third new locus is defined by rs9315204 at 13q13.1 (OR = 1.20; P = 2.5×10-9; PPA = 
0.9981) in intron 7 of STARD13 (StAR-related lipid transfer (START) domain containing 
13) (Fig. 2). Two SNPs, rs1980781 and rs3742321, that are strongly correlated with 
rs9315204 (r2 > 0.9) also showed significant association with IA (Fig. 2 and Supplementary 
Table 4). These two SNPs are missense (lysine to arginine) and synonymous coding variants 
of STARD13, respectively. Another gene that has been implicated in aging phenoytpes, KL 
(klotho), is located nearby13.
A search of the gene-expression database (eQTL browser, http://eqtl.uchicago.edu/) for all 
the IA-risk loci did not reveal any consistent pattern of association of IA SNPs with 
variation in gene expression levels.
In this second GWAS of IA, which included nearly 3 times as many cases as the initial 
study, we detected 3 novel risk loci and obtained strong independent evidence for 
association of 2 previously identified loci. The evidence that these are bona fide risk loci for 
IA is very strong from both Bayesian measures and conventional P-values.
Given our power (Ԉ90%) to detect variants that confer risk of IA with GRR = 1.25 and 
MAFs ≥ 10%, we expect that we have identified most of these variants, limited principally 
by potential gaps in SNP coverage. Indeed, across the rest of the genome, there was no locus 
with PPA > 0.22 and MAF ≥ 10%, while there were 14 loci with PPAs between 0.1 and 0.22 
and ORs between 1.16 and 1.25 (data not shown). We expect that a fraction of these loci are 
genuine IA risk loci, as suggested by the excess of SNPs with P < 1×10-3 (Fig. 1b); 
exploring this possibility will require analysis of still larger IA cohorts and/or genotyping of 
alleles with lower MAF.
Based on the results of the first GWAS of IA and the role of the implicated gene products, 
Sox17 and p15INK4b/p16INK4a, we previously hypothesized2 that the IA genes implicated 
might play a role in determining cell cycle progression, affecting proliferation14 and 
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senescence of progenitor cell populations and/or the balance between production of 
progenitor cells versus cells committed to differentiation. Genes located within the newly 
identified regions support this idea. RBBP8, located within the 18q11.2 region, influences 
progression through the cell cycle by interacting with BRCA115. Similarly, of the two genes 
located within the 13q13.1 interval, STARD13 contains Rho-GAP and C-terminal STAR 
related lipid transfer (START) domains and its overexpression results in suppression of cell 
proliferation16. The other gene, KL, encodes a transmembrane protein that modulates FGF 
receptor specificity17; KL-deficient mice display accelerated aging in diverse organ 
systems13.
On the assumption that there is a four-fold increase in the risk of IA among siblings of 
cases18,19 and that the SNPs combine to increase log-odds of disease in an additive fashion, 
the 5 IA risk loci explain 5.2% (FI), 4.0% (CE) and 3.5% (combined JP1 and JP2) of the 
familial risk of IA. Under this model, the odds of developing IA varies 4.99 to 7.63 fold 
across the top and bottom 1% of genetic risk profile at these loci in these populations and 
3.61 to 4.64 fold across the 5% extremes (Supplementary Fig. 2). When combined with 
traditional risk factors such as gender, blood pressure and smoking, these findings form the 
basis of future work aimed at pre-clinical identification of individuals who are at high risk of 
IA formation and rupture.
Online Methods
Genotyping
Whole-genome genotyping for discovery cohort was performed on the Illumina platform 
according to the manufacturer' s protocol (Illumina, SanDiego, CA, USA). Beadchips used 
for individual cohorts are presented in Supplementary Table 2. Replication genotyping in the 
JP1 cohort was performed using either Taqman (Applied Biosystems) or MassARRAY 
(Sequenom) assays. For the JP2 cohort, genotyping for cases was performed using the 
multiplex PCR-based Invader assay (Third Wave Technologies Inc.); genotyping for 
controls was performed on Illumina platform as described previously20.
Ethics
The study protocol was approved by the Yale Human Investigation Committee (HIC 
protocol #7680). Institutional review board approval for genetic studies, along with written 
consent from all study participants, was obtained at all participating institutions.
Data storage and analysis tools
We used PLINK21 v1.06 and R statistical environment v2.9.0 (in particular, the snpMatrix 
package22) for storage of genotype data and data analysis.
Preprocessing
Prior to the analysis of genotyping data, we excluded SNPs that were located either on 
mtDNA or sex chromosomes; with A/T or C/G alleles; for which all subjects were assigned 
as ‘ no call’ ; and assayed on Hap300v1 or 550v1 but dropped from newer versions.
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Sample quality control (QC)
We excluded subjects in the discovery cohort that did not conform to our study design on 
the basis of genotyping and information quality, cryptic relatedness and population outliers. 
We summarized the sample exclusion steps in Supplementary Table 2. This filtering process 
resulted in 835 cases and 6,529 controls in the Finnish (FI) cohort and 2,000 cases and 8,722 
controls in the rest of the combined European (CE) cohort.
Imputation
We performed imputation analysis with the HapMap phase II CEU reference panel (release 
24) using the IMPUTE v1 software6. The analysis was performed separately for the FI and 
CE cohorts. We converted posterior probabilities of three possible genotypes to the 
fractional allele dosage scores (between 0 and 2) and used these scores for association tests 
in order to take into account the imputation uncertainty23. For the quality assessment of 
imputed SNPs, we also converted the posterior probabilities to the most likely genotypes 
with the threshold at 0.9.
Case-control matching
Population stratification and independent genotyping of cases and controls are major causes 
of confounding in genome-wide association studies24. Because our study consisted of 
multiple independently ascertained cohorts that were genotyped separately, we performed a 
stringent analysis to control for these biases by inferring genetic ancestries of subjects25,26. 
We used the Laplacian eigenmaps27 to infer population structure. Following the 
determination of the number of dimensions (K + 1) using the threshold given in Lee et al.28, 
we used the K-dimensional non-trivial generalized eigenvectors29 to calculate the Euclidean 
distance between two subjects.
In the course of this analysis, we excluded “ isolated”  subjects who were identified by using 
the nearest-neighbor distance distributions in any of the 2-dimensional sections. After 
excluding these subjects, we observed 13 and 5 dimensions in FI and CE, respectively. The 
larger dimensions observed in FI could be attributable to the presence of many isolated 
populations in Finland5.
Before matching, we stratified data into males and females because female gender is a 
known risk factor of IA1,3. We also set the maximum distance between cases and controls to 
match to be less than 0.028 and 0.009 in FI and CE cohorts, respectively. These values were 
determined by examining the distribution of the nearest-neighbor distances in K-dimensions 
(data not shown). We matched cases and controls using the fullmatch function in the R-
package optmatch30,31.
SNP quality control
For both genotyped and imputed SNPs in the discovery cohort, we applied QC filters to 
individual cohorts and to cases and controls separately, on the basis of the missing rate, 
minor allele frequency (MAF) and the P-value of the exact test of Hardy-Weinberg 
equilibrium (HWE)32. For imputed SNPs, we also assessed imputation quality using the 
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average posterior probability, MAF and allelic R2 metric33. Finally, we assessed differential 
missingness between cases and controls (Supplementary Table 2).
Any genotyped SNP that passed the QC filters both in the CE and FI cohorts is referred to as 
a “ genotyped SNP”  while one for which we used the QC-passed imputation data either in 
one or both of the cohorts is classified as an “ imputed SNP” .
For genotyping data of the replication cohorts, we excluded SNPs if any of the following 3 
conditions were met in either cases or controls: (i) missing rate > 0.05; (ii) P-value of the 
exact test of HWE < 0.001; or (iii) MAF < 0.01.
Statistical analysis
Cohort-wise association analysis—We tested for association between each QC-passed 
SNP and IA using the conditional and unconditional logistic regression for the discovery and 
replication cohorts, respectively34. For the discovery cohort, we used the matched strata to 
correct for potential confounding due to population stratification and gender, while for the 
replication cohorts we adjusted for gender. We assumed the log-additive effect of allele 
dosage on disease risk. We obtained P-values from the score test (two-sided) and estimated 
the logarithm of per-allele odds ratios (ORs) with standard errors (SEs) by maximizing the 
(conditional or unconditional) likelihood. Both the test statistic and the SE of log-OR were 
corrected using genomic control7. We performed the association analysis for FI and CE, as 
well as sub-cohorts of CE that consisted of NL cases, DE cases or @neurIST cases and their 
matched controls (Table 1 and Supplementary Table 3). We used the following R-functions 
to perform the association analysis: clogit, glm and snp.rhs.tests22.
Meta-analysis—We combined the cohort-wise per-allele ORs in FI and CE using a fixed-
effects model of meta-analysis for 831,534 QC-passed SNPs to obtain the discovery results. 
For SNPs analyzed both in the discovery and replication cohorts, we combined JP1 and JP2 
to obtain replication results and all 4 cohorts to obtain combined results. Our primary 
analysis was based on the fixed-effects model23. In order to assess the heterogeneity of the 
effect size between cohorts, we first divided CE into 3 cohorts as described above, aiming to 
analyze data without averaging effect sizes over the combined European cohorts, and then 
combined 6 cohorts using the random-effects model. We employed the restricted maximum 
likelihood procedure to estimate the between-cohort heterogeneity variance (Ŭ2) using the 
R-function MiMa35 (http://www.wvbauer.com/). From this estimate, we calculated the 
Cochran' s Q statistic and the I2 statistic36.
Bayesian evaluation of the strength of association—To evaluate the strength of 
association, we employed a Bayesian approach9,37. A limitation of the use of P-values alone 
is that variability in factors such as effect size, MAF and sample size can result in identical 
statistics that might correspond to markedly different levels of evidence regarding the 
strength of association10. The Bayes factor (BF) provides an alternative that compares the 
probabilities of the data under the alternative hypothesis versus the null hypothesis. For 
computational simplicity, we approximated BF as described by Wakefield8. For all SNPs, 
we assumed a single prior for the log-OR: a normal distribution with mean 0 and standard 
deviation log(1.5)/ Ŏ-1(0.975), where Ŏ is the normal distribution function9.
Yasuno et al. Page 7
Nat Genet. Author manuscript; available in PMC 2010 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
The posterior probability of association10 (PPA) provides a simple probabilistic measure of 
evidence by introducing the prior probability of association, Ũ1. We assumed a uniform 
prior, Ũ1 = 1/10,000, for all the SNPs11. For BF > 106, changing Ũ1 to a more conservative 
value of 1/100,000 would result in little change in the posterior probability of association.
To combine the results from multiple cohorts, we extended the formula38 to be applicable to 
multiple (> 2) cohorts.
Conditional analysis—For each region that contained a SNP with PPA > 0.5, we 
examined the number of independent association signals by testing for association of every 
genotyped SNP with IA by adjusting for the effect of a specified SNP (Supplementary Fig. 
1).
Two-locus interaction analysis—We tested for deviation from a linear model, which 
assumes that two SNPs combine to increase the log-odds of disease in an additive fashion, 
using conditional (FI and CE) or unconditional (JP: JP1 plus JP2, stratified by cohorts and 
gender) logistic regression. There was no significant deviation from the linear model (data 
not shown).
Cumulative effect—We evaluated potential clinical implications of the genetic profiles of 
the 5 IA risk loci following the approach described by Clayton39. We fitted a 5-locus 
conditional (FI and CE) or unconditional (JP) logistic regression model including the 
additive and dominance-deviation terms for each locus. Using the estimated effect sizes and 
individual' s genotypes, we calculated the risk scores for every individual. The receiver-
operating characteristic (ROC) curve for each ethnic cohort (FI, CE and JP) was depicted 
using the risk score.
We also calculated the ratio of the exponential of the mean of the risk scores for control 
subjects within the top versus bottom 5 or 1% to obtain approximated odds ratios of disease 
between these classes.
The sibling recurrence risk was estimated by assuming the polygenic model that fits well to 
our data39. Fraction of the sibling recurrence risk attributable to all of the 5 loci was 
calculated by taking the ratio of the logarithm of this value and epidemiologically estimated 
value of 418,19.
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Figure 1. Genome-wide association analysis results in the discovery cohort
(a) The posterior probabilities of association (PPAs) for 831,532 QC-passed SNPs analyzed 
specifying a prior probability of association of 1/10,000 are plotted against genomic 
locations of SNPs. A gray horizontal line at PPA = 0.5 indicates the cutoff value for follow-
up genotyping. (b) Quantile-quantile (QQ) plots of P-values (−log10 scale) are shown for: all 
the SNPs analyzed (black; n = 831,532); SNPs after excluding those within previously 
identified regions (red; n = 830,907); SNPs after excluding all within the final associated 
intervals (blue; n = 830,158). (c) A scatter plot of −log10 P-values vs. log10 Bayes factors 
(BFs) is shown with color for each point indicating the range of PPA. There are very close 
relationships among the P-value for association, the BF and PPA. Note that, given a uniform 
prior probability of association, the PPA increases as the BF increases. A vertical line 
indicates the minimum PPA threshold at 0.5 (BF = 1.0×104) for follow-up.
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Figure 2. Regional plots for associated regions
For each chromosomal interval, −log10 P-values for association are plotted against the 
genomic coordinates (NCBI build 36) in the upper panel; the recombination rates obtained 
from the HapMap database and the RefSeq genes (hg18) within the regions are shown in the 
lower panel. In the upper panel, rs identifiers of SNPs listed in Table 2 are shown and their 
positions are indicated by gray vertical lines. Gray dashed lines indicate locations of other 
SNPs genotyped in the replication cohorts. Dark blue and light blue dots represent results of 
genotyped and imputed SNPs for the discovery cohort, respectively; orange and light orange 
squares represent association results for the replication cohort using JP1 plus JP2 and JP2-
only, respectively; combined results for SNPs genotyped both in the discovery and the 
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replication cohort using JP1 plus JP2 and JP2-only are shown by red and light red diamonds, 
respectively.
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Figure 3. Consistency of association across cohorts
Forest plots are shown for meta-analysis of SNPs listed in Table 2. Squares and horizontal 
segments represent estimated per-allele odds ratios (ORs) and 95% confidence intervals 
(CIs) for individual cohorts. Diamonds represent the summary OR estimates and 95% CIs 
for the meta-analyses of 6 cohorts (fixed- and random-effects models). log10(BF) > 0 
supports association with IA, while log10(BF) < 0 supports no association with IA. 
Analyzing the results here as 6 distinct cohorts rather than 4 (as in the primary analysis) 
results in only minor differences, due to different weights given to sub-cohorts of the 
combined European cohort (CE) associated with genomic control correction.
Yasuno et al. Page 16
Nat Genet. Author manuscript; available in PMC 2010 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript
Y
asuno et al.
Page 17
Table 1
Overview of the study cohorts
Cohort Case (n) Control (n) Number of QC-passed SNPs Genomic inflation factor
Discovery Finland (FI) 808 4,393 1,303,876 1.07
Combined European (CE) 1,972 8,122 905,906 1.09
Total discovery 2,780 12,515 831,532 1.007
CE sub-cohorts NL 708 3,954 905,906 1.11
DE 789 2,228 905,906 1.06
AN 475 1,940 905,906 1.06
Replication Japan 1 (JP1) 829 761 12
Japan 2 (JP2) 2,282 905 13
Total replication 3,111 1,666 12
Total 5,891 14,181 12
Combined European (CE) cohort consisted of all European subjects who were not ascertained in Finland. Sub-cohorts of CE were defined on the basis of case series: NL = Cases from the Netherlands with 
matched controls; DE = German cases with matched controls; AN = @neurIST cases with matched controls. NL, DE and AN were exclusive subsets of CE (see also Supplementary Table 3). AN cases 
consisted of subjects from Germany, Great Britain, Hungary, the Netherlands, Switzerland and Spain. JP1 and JP2 were 2 independent Japanese case-control cohorts. Genomic inflation factors of FI and CE 
(as well as NL, DE and AN) were calculated for 1,303,876 and 905,906 SNPs, respectively. The genomic inflation factor of the discovery cohort (“ Total discovery”  row) was based on the meta-analysis 
result for 831,532 SNPs after correcting each cohort for genomic control. The discovery data (combined FI and CE) was not corrected for genomic control.
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Table 2
Representative SNPs analyzed both in the discovery and replication cohorts
Locus SNP Position Genes Risk Allele Cohort P-value log10(BF) PPA Per-allele OR (95% CI) Control RAF Case RAF
8q11.23 rs10958409 55,489,644 SOX17 A Discovery 4.2×10-07 4.64 0.8128 1.24 (1.14-1.35) 0.15, 0.19 0.18, 0.22
Replication 0.12 -0.11 1.08 (0.98-1.20) 0.28 0.29
Combined 9.0×10-07 4.30 0.6685 1.17 (1.10-1.25)
8q12.1 rs9298506 55,600,077 SOX17 A Discovery 1.2×10-10 7.94 0.9999 1.33 (1.22-1.45) 0.81, 0.76 0.85, 0.81
Replication 0.0012 1.56 1.21 (1.08-1.36) 0.79 0.81
Combined 1.3×10-12 9.85 1.0 –  1.4×10-06 1.28 (1.20-1.38)
9p21.3 rs1333040 22,073,404 CDKN2A, CDKN2B T Discovery 2.5×10-16 13.41 1.0 –  3.9×10-10 1.32 (1.24-1.41) 0.56, 0.45 0.63, 0.53
Replication 1.0×10-07 5.18 1.31 (1.19-1.45) 0.66 0.72
Combined 1.5×10-22 19.48 1.0 –  3.3×10-16 1.32 (1.25-1.39)
10q24.32 rs12413409 104,709,086 CNNM2 G Discovery 7.9×10-07 4.29 0.6621 1.38 (1.22-1.57) 0.91, 0.91 0.94, 0.93
Replication 0.00014 2.34 1.23 (1.10-1.37) 0.74 0.77
Combined 1.2×10-09 7.00 0.9990 1.29 (1.19-1.40)
13q13.1 rs9315204 32,591,837 KL, STARD13 T Discovery 3.3×10-07 4.73 0.8443 1.21 (1.13-1.31) 0.21, 0.33 0.24, 0.39
Replication 0.0019 1.36 1.18 (1.06-1.31) 0.24 0.27
Combined 2.5×10-09 6.72 0.9981 1.20 (1.13-1.28)
18q11.2 rs11661542 18,477,693 RBBP8 C Discovery 5.6×10-09 6.39 0.9959 1.21 (1.14-1.30) 0.49, 0.44 0.54, 0.47
Replication 4.5×10-05 2.79 1.22 (1.11-1.34) 0.61 0.65
Combined 1.1×10-12 9.92 1.0 –  1.2×10-06 1.22 (1.15-1.28)
Genomic locations for SNPs are based on NCBI build 36 and risk alleles are aligned to the forward strand of the reference sequence. Control and case risk allele frequencies (RAFs) for the discovery cohort 
are shown in the form: (RAF of CE), (RAF of FI). log10(BF) indicates the logarithm of the Bayes factor in favor of association. PPA stands for the posterior probability of association. Genes closest to the 
listed SNPs within the same linkage disequilibrium regions are shown.
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